|
Mar 4
|
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
|
|
Jan 8
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jan 5
|
Ecstasy-for-Medicine Advocate Raises $100 Million
|
|
Jan 4
|
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
|
|
Nov 14
|
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
|
|
Aug 8
|
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
|
|
May 2
|
atai Life Sciences to Participate in Upcoming May Investor Conference
|
|
Apr 28
|
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
|